July 1, 2017 -- Deals and Financings
--Shandong Sinobioway offered $459 million to acquire Beijing vaccine maker Sinovac, a 14% premium to management’s earlier privatization bid;
--AGIC Capital of Hong Kong will acquire Ritedose Corporation, a US formulation/blow-fill-seal company, for approximately $700 million;
--Guangzhou broke ground on a major new $800 million biopharma park partnered with General Electric;
--CSPC Pharma of Hong Kong acquired global rights to two pre-clinical drug candidates from University of Texas institutions in a $114 million deal;
--Vivace Therapeutics, a Bay-area oncology company, raised $40 million in two venture rounds from China-US investors; --Zai Lab, a Shanghai novel drug development/in-licensing company, closed a $30 million Series C round;
--iCarbonX, a China big data/AI startup, participated in a $8.4 million series B funding of HealthLoop, a California company that facilitates patient-doctor contact;--India’s Biological E. Limited in-licensed rights to two Takeda vaccines for India, China and low/middle income countries;
Trials and Approvals
--Hutchison China MediTech (Chi-Med) and AstraZeneca announced the start of a global Phase III trial of their partnered drug, the c-MET inhibitor savolitinib, for US-Europe approvals. More details....
